Although the small sample size is an inherent limitation of the study, it could help in collecting new data at a faster rate and prompt extending our understanding of MET alterations in lung cancers, such as whether MET exon 14 skipping mutations result in MET protein overexpression or not. This evidence concerns the gene MET and lung cancer.